Compare
20/20 Biolabs, Inc. vs iSpecimen Inc. vs Absci Corp vs OneMedNet Corp
| Latest fiscal year | 20/20 Biolabs, Inc. AIDX | iSpecimen Inc. ISPC | Absci Corp ABSI | OneMedNet Corp ONMD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $2.05M | $1.93M | $2.80M | $1.36M |
| Revenue growth (YoY) | +16.7% | -79.2% | -38.2% | +111.4% |
| Gross margin | 29.6% | 1.2% (computed) | n/a | -37.0% |
| Operating margin | -162.9% | -465.4% | n/m | -711.3% |
| Net margin | -182.8% | -543.7% | n/m | -206.1% |
| Net income | -$3.74M | -$10.49M | -$115.18M | -$2.80M |
| EPS (Diluted) | -$0.76 | -$2.28 | -$0.84 | -$0.06 |
| Operating cash flow | -$1.92M | -$4.24M | -$92.92M | -$7.50M |
| Free cash flow | n/a | -$4.24M | -$94.03M | -$7.52M |
| Cash & equivalents | $1.03M | $6.88M | $20.02M | $585.0K |
| Total assets | $4.14M | $9.53M | $216.30M | $2.15M |
| Total liabilities | $4.16M | $6.44M | $26.85M | $5.12M |
| Shareholders' equity | -$19.2K | $3.09M | $189.45M | -$2.96M |
| Return on year-end equity | n/a | -339.6% | -60.8% | n/a |
| Shares outstanding | 5.44M | 8.48M | n/a | 51.98M |
Revenue, most recent five fiscal years
| Fiscal year | 20/20 Biolabs, Inc. | iSpecimen Inc. | Absci Corp | OneMedNet Corp |
|---|---|---|---|---|
| Latest | $2.05M Ended 2025-12-31 | $1.93M Ended 2025-12-31 | $2.80M Ended 2025-12-31 | $1.36M Ended 2025-12-31 |
| 1 year earlier | $1.75M Ended 2024-12-31 | $9.29M Ended 2024-12-31 | $4.53M Ended 2024-12-31 | $643.0K Ended 2024-12-31 |
| 2 years earlier | n/a | $9.93M Ended 2023-12-31 | $5.72M Ended 2023-12-31 | $1.02M Ended 2023-12-31 |
| 3 years earlier | n/a | $10.40M Ended 2022-12-31 | $4.53M Ended 2022-12-31 | $1.15M Ended 2022-12-31 |
| 4 years earlier | n/a | $11.14M Ended 2021-12-31 | $4.01M Ended 2021-12-31 | n/a |